Galmed Pharmaceuticals Ltd. filings document the company’s foreign private issuer reporting, Aramchol development disclosures and public-company governance matters. Recent Form 6-K reports furnish press releases on Aramchol-based collaborations, brain-penetrating formulation work, scientific presentations, Nasdaq minimum bid price correspondence and shareholder meeting materials.
The filing record also includes proxy and voting materials for special general meetings, incorporation of selected 6-K disclosures into Form S-8 and Form F-3 registration statements, and references to the company’s ordinary shares. These documents describe governance procedures, capital-market registration matters, listing-status communications and development updates for Galmed’s clinical-stage biopharmaceutical business.
Galmed Pharmaceuticals Ltd. filed a Form 3 showing Chief Financial Officer Doron Leib Cohen’s existing equity holdings in the company. He directly holds 22,083 Ordinary Shares, several blocks of Restricted Share Units, and options to purchase 208 Ordinary Shares at an exercise price of 68.4000 per share expiring on February 23, 2032.
One RSU grant of 2,083 units vests on August 7, 2026, another of 23,333 units vests in four equal parts on May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, and a further RSU award of 25,000 units vests one-third on August 26, 2026 with the rest in four installments through August 26, 2028, all subject to his continued service.
Galmed Pharmaceuticals Ltd. director and CEO Baharaff Allen has filed an initial statement of holdings, detailing his equity position in the company. He directly owns 103,047 ordinary shares and has an additional 18 ordinary shares beneficially owned through his spouse.
He also holds options to purchase ordinary shares, including grants exercisable for 1,222 shares at exercise prices of 599.4000, 921.6000, and 2080.8000 per share, expiring between 2028 and 2030, plus options over 1,805 shares at an exercise price of 0.0020 per share expiring in 2028.
In addition, he reports restricted share units, including 8,889 units that vest on August 7, 2026, 96,666 units vesting in four equal installments between May 12, 2026 and November 12, 2027, and 100,000 units vesting between August 26, 2026 and August 26, 2028, all subject to his continued service. The filing reflects holdings only and does not show new buy or sell transactions.
Galmed Pharmaceuticals Chief Accounting Officer Yohai Stenzler filed an initial ownership report showing direct holdings of 22,116 Ordinary Shares of GLMD. He also holds several equity awards and options that may convert into additional shares over time.
The filing lists options to purchase Ordinary Shares with an exercise price of 68.4000 per share, covering 222, 222, 111 and 222 underlying shares expiring between 2027 and 2030. Restricted share units include 2,083 units vesting on August 7, 2026, 23,333 units vesting in four installments from May 12, 2026 through November 12, 2027, and 25,000 units vesting between August 26, 2026 and August 26, 2028, all subject to his continued service.
Galmed Pharmaceuticals Ltd. Chief Scientific Officer Liat Nissimov Brueck filed an initial statement of beneficial ownership, reporting direct holdings of employee stock options. These options allow her to purchase Ordinary Shares at an exercise price of 68.4000 per share, with individual grants covering 222, 181 and 153 underlying shares. The options have staggered exercise and expiration dates ranging from 2016-09-06 to 2030-11-10, showing a series of long-term equity awards rather than new market transactions.
Galmed Pharmaceuticals director Amir Poshinski has reported his initial ownership position in the company. The filing shows direct holdings of ordinary shares, multiple restricted share unit grants that vest over several dates through 2028, and stock options over 111 and 166 ordinary shares at exercise prices of 558.0000 and 2080.8000, expiring in 2031 and 2028 respectively.
Galmed Pharmaceuticals Chief Operating Officer Nehemya Guy filed an initial ownership report showing his equity stake in the company. He directly owns 22,116 Ordinary Shares, along with stock options and multiple restricted share unit (RSU) awards.
He holds three option grants to purchase Ordinary Shares, each covering 222 underlying shares at an exercise price of $68.40, with expiration dates in 2028, 2029, and 2030. In addition, he holds RSU awards covering 2,083, 23,333 and 25,000 shares that vest between 2026 and 2028, subject to his continued service.
Galmed Pharmaceuticals Ltd. director Nir Shmuel filed an initial ownership report showing his equity position in the company. He directly holds 11,286 Ordinary Shares, stock options over 111 and 166 underlying Ordinary Shares with exercise prices of 558.0000 and 2080.8000, and several Restricted Share Unit (RSU) grants totaling thousands of units.
The RSUs vest over time, subject to his continued service, including one grant vesting on August 7, 2026, another in four equal installments on May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, and a third grant vesting from August 26, 2026 through August 26, 2028.
Galmed Pharmaceuticals Ltd. director Carol L. Brosgart filed an initial ownership report showing she holds several option grants to purchase Ordinary Shares. The options have exercise prices ranging from 1.4100 to 2080.8000 and expiration dates from 2027-04-25 through 2035-10-29. Footnotes state that portions of these options vest in stages between 2026 and 2028, subject to her continued service.
Galmed Pharmaceuticals Ltd. reported that it held a Special General Meeting of Shareholders on March 5, 2026. At this meeting, shareholders voted on a proposal described in the proxy statement that was previously furnished to the SEC on February 9, 2026. The proposal was approved by the required majority under the Israeli Companies Law, meaning it received enough votes for adoption under Galmed’s home-country rules. The company also noted that this report is incorporated by reference into its existing registration statements on Form S-8 and Form F-3, linking the meeting outcome into its broader U.S. securities registration framework.
Galmed Pharmaceuticals Ltd. postponed its Special General Meeting of Shareholders because too few shareholders were present to meet the required quorum. The meeting, originally convened on March 4, 2026, will reconvene on March 5, 2026 at 4:00 p.m. Israel time at the offices of Meitar Law Offices in Ramat Gan. The report also states that this information is incorporated by reference into Galmed’s existing Form S-8 and Form F-3 registration statements.